{
  "actions": [
    {
      "acted_at": "2012-03-28",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2012-03-28",
      "action_code": "H11100",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Energy and Commerce.",
      "type": "referral"
    },
    {
      "acted_at": "2012-03-30",
      "action_code": "",
      "committees": [
        "HSIF"
      ],
      "references": [],
      "text": "Referred to the Subcommittee on Health.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr4274-112",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF"
    },
    {
      "activity": [
        "referral"
      ],
      "committee": "House Energy and Commerce",
      "committee_id": "HSIF",
      "subcommittee": "Subcommittee on Health",
      "subcommittee_id": "14"
    }
  ],
  "congress": "112",
  "cosponsors": [
    {
      "bioguide_id": "E000215",
      "district": "14",
      "name": "Eshoo, Anna G.",
      "original_cosponsor": true,
      "sponsored_at": "2012-03-28",
      "state": "CA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "M000133",
      "district": "7",
      "name": "Markey, Edward J.",
      "original_cosponsor": true,
      "sponsored_at": "2012-03-28",
      "state": "MA",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2012-03-28",
  "number": "4274",
  "official_title": "To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003.",
  "popular_title": null,
  "related_bills": [
    {
      "bill_id": "hr5651-112",
      "identified_by": "CRS",
      "reason": "related",
      "type": "bill"
    }
  ],
  "short_title": "BPCA and PREA Reauthorization Act of 2012",
  "sponsor": {
    "bioguide_id": "R000572",
    "district": "8",
    "name": "Rogers, Mike J.",
    "state": "MI",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2012-03-28",
  "subjects": [
    "Administrative law and regulatory procedures",
    "Advisory bodies",
    "Cancer",
    "Child health",
    "Congressional oversight",
    "Consumer affairs",
    "Department of Health and Human Services",
    "Drug safety, medical device, and laboratory regulation",
    "Drug therapy",
    "Food and Drug Administration (FDA)",
    "Government information and archives",
    "Health",
    "Intellectual property",
    "Medical research",
    "Prescription drugs"
  ],
  "subjects_top_term": "Health",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2012-03-28",
    "date": "2012-06-13T17:01:07Z",
    "text": "BPCA and PREA Reauthorization Act of 2012 - Makes permanent the provisions of the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act of 2003 (PREA).\n\nAmends the Federal Food, Drug, and Cosmetic Act to revise provisions concerning pediatric research requirements and the granting of exclusivity.\n\nExtends the period for mandatory reporting of adverse events to the Office of Pediatric Therapeutics to 18 months after an approved label change.\n\nRequires a product sponsor to submit an Initial Pediatric Plan as part of the drug application process and sets forth the process for such submission.\n\nAuthorizes the Secretary of Health and Human Services (HHS) to: (1) grant a deferral extension, and sets forth the conditions for such deferral; and (2) issue a non-compliance letter to a product sponsor failing to meet post-marketing requirements, and requires the product sponsor to respond in writing.\n\n Authorizes the Pediatric Review Committee to review deferral extensions.\n\nRequires the Office of Pediatric Therapeutics to include a neonatologist and pediatric epidemiologist.\n\nReauthorizes the Pediatric Advisory Committee and the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee."
  },
  "titles": [
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "BPCA and PREA Reauthorization Act of 2012",
      "type": "short"
    },
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "BPCA and PREA Reauthorization Act of 2012",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003.",
      "type": "official"
    }
  ],
  "updated_at": "2019-11-15T21:18:14Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/112/hr/BILLSTATUS-112hr4274.xml"
}